

### **Company Update**

**December 7, 2018** 


# Rating matrix Rating : Hold Target : ₹ 1045 Target Period : 12 months Potential Upside : 9%

Changed from ₹ 1090 to ₹ 1045
Unchanged
Unchanged
Changed from Buy to Hold

<b>Key Financials</b>				
₹ Crore	FY17	FY18	FY19E	FY20E
Net Sales	46,723	50,570	60,648	66,856
EBITDA	9,474	9,987	12,130	13,371
Net Profit	8,457	8,780	10,131	10,909
EPS (₹)	60.0	62.6	74.7	80.5

Valuation summ	ary			
	FY17	FY18	FY19E	FY20E
P/E	16.0	15.3	12.8	11.9
Target P/E	17.4	16.7	14.0	13.0
EV / EBITDA	13.0	11.5	9.1	7.9
P/BV	4.0	3.7	3.4	3.0
RoNW (%)	25.3	23.8	26.5	24.8
RoCE (%)	29.0	27.4	32.0	31.0

#### **Price Chart**



#### Research Analyst

Devang Bhatt devang.bhatt@icicisecurities.com

Deepti Tayal deepti.tayal@icicisecurities.com

# **HCL Technologies (HCLTEC)**

₹ 960

## To acquire IBM products for \$1.8 billion...

HCL Technologies (HCLT) has signed a definitive agreement to acquire select IBM software products for \$1.8 billion. The HCLT management expects incremental revenue of \$625 million in the first year and \$650 million in the second year after deal closure. The EBITDA margin of the acquired products is expected to be ~50% with cash EPS accretive by 15%. The transaction is expected to be closed by mid-2019 subject to completion of applicable regulatory reviews. Our key concern in the transaction is around sustenance of margins at 50% (post acquisition), risk of revenues from IP products not fully materialising, lower focus on organic growth and near term pressure on cash flows. Hence, we downgrade the stock from BUY to HOLD.

#### HCLT-IBM \$1.8 billion deal...

In its biggest acquisition amounting to US\$1.8 billion including earn-out, HCLT would acquire seven IBM software products ranging from security collaboration, management, enterprise digital experience ecommerce. As per the management, software products in scope represent a total addressable market of more than \$50 billion and would enhance client interactions and cross-selling opportunities. Looking from the perspective of financial transactions, ~48% of the consideration (\$1.8 billion) is to be paid at the closure of the deal (expected mid-2019) while most of the remaining balance (52%) is to be paid after the first year post deal closure (estimated mid-2020). Further, the investment would be funded through a debt of \$300 million at close and internal accruals. Cash and cash equivalents were at US\$1,594 million at the end of Q2FY19. From the viewpoint of revenue accretion, the HCLT management expects incremental revenue of \$625 million in the first year and \$650 million on a run rate basis in the second year after deal closure. As per the management, the EBITDA margin of the acquired products is expected to be  $\sim$ 50% on a run rate basis and cash EPS accretive by 15%.

#### Sceptical about growth driven by acquisitions...

Out of the seven products acquired by the company, it already has a partnership in five products for which the company has invested \$800 million taking the total investment to \$2.6 billion. We believe this huge investment puts pressure on the company's cash flow and adds debt to the balance sheet. Further, considering the volatile nature of IP revenues, it could also cast a shadow of doubt on revenue growth as well as margin sustenance at current level. Adding this acquisition in its portfolio, going ahead, the split of organic and inorganic growth would shift more towards the latter, implying a weaker organic growth trajectory. Moreover, if the deal does not ramp up as per expectations it could act as a downside risk to profitability. We are not incorporating the acquisition into our estimates as of now on account of awaited regulatory reviews.

#### Near term concerns prompt us to downgrade to HOLD...

We believe HCLT's continuous investments in IP and acquisitions could mount pressure on its profitability on account of the volatile nature of IP business and slow ramp of revenues through acquisitions. Hence, we lower our valuation multiple to 13x FY20E EPS (earlier  $\sim 14x$ ) owing to a dim view on organic growth and scepticism around sustenance of revenues & margins in acquired assets along with near term pressure on cash flows. Hence, we have a **HOLD** recommendation on the stock with a revised target price of ₹ 1045 per share.



## **Financial summary**

Profit and loss statement			;	₹ Crore
	FY17	FY18	FY19E	FY20E
Total operating Income	46,723	50,570	60,648	66,856
Growth (%)	14.2	8.2	19.9	10.2
Direct costs	30,890	33,237	39,239	43,256
S,G&A expenses	5,524	5,894	7,096	7,822
Total Operating Expenditure	36,414	39,131	46,335	51,078
EBITDA	10,309	11,440	14,313	15,778
Growth (%)	17.2	11.0	25.1	10.2
Depreciation	771	1,453	2,183	2,407
Amortisation	64	-	-	-
Other Income	746	570	647	797
PBT	10,220	10,557	12,776	14,168
Forex adjustments	-	-	-	-
Total Tax	1,952	2,316	2,857	3,259
PAT	8,457	8,780	10,131	10,909
Growth (%)	15.0	3.8	15.4	7.7
EPS (₹)	60.0	62.6	74.7	80.5
Growth (%)	15.2	4.3	19.4	7.7

Source: Company, ICICI Direct Research

Balance sheet			₹	Crore
	FY17	FY18	FY19E	FY20E
Liabilities				
Equity Capital	283	278	271	271
Reserve and Surplus	33,208	36,538	37,935	43,739
Total Shareholders funds	33,490	36,817	38,206	44,010
Total Debt	542	437	437	43
Other liabilities + Provisions	1,253	1,267	1,267	1,267
Minority Interest / Others	-	-	-	
Total Liabilities	35,285	38,521	39,910	45,714
Assets				
Net Block+ CWIP	4,681	5,185	4,518	3,78
ntangible assets	11,426	14,406	14,406	14,40
nvestments	10,366	6,249	6,249	6,24
Liquid investments	1,146	2,357	2,357	2,35
Inventory	-	-	-	
Debtors	10,803	12,258	14,556	16,04
Loans and Advances	-	-	-	
Other Current Assets	2,983	2,520	3,022	3,33
Cash	1,317	1,694	2,926	8,88
Total Current Assets	16,248	18,828	22,861	30,61
Total Current Liabilities	11,148	9,914	11,890	13,10
Net Current Assets	5,100	8,914	10,971	17,510
Other non current assets	3,712	3,768	3,768	3,768
Application of Funds	35,285	38,521	39,910	45,714

Source: Company, ICICI Direct Research

Cook floor statement			<b>∓</b> 0.	
Cash flow statement			₹ Cı	
	FY17	FY18	FY19E	FY20E
PBT	10,220	10,557	12,776	14,168
Depreciation & Amortisation	835	1,453	2,183	2,407
(Inc)/dec in Current Assets	(653)	(992)	(2,800)	(1,799)
Inc/(dec) in CL and Provisions	1,639	(1,233)	1,976	1,217
Taxes paid	(1,952)	(2,316)	(2,857)	(3,259)
CF from operating activities	9,532	7,440	10,843	11,937
(Inc)/dec in Investments	746	570	647	797
(Inc)/dec in Fixed Assets	(1,168)	(1,264)	(1,516)	(1,671)
CF from investing activities	(422)	(694)	(870)	(875)
Issue/(Buy back) of Equity	-	(3,500)	(4,000)	-
Inc/(dec) in loan funds	(69)	-	-	-
Dividend paid & dividend tax	(3,972)	(1,955)	(4,741)	(5,106)
Inc/(dec) in debentures	-	-	-	-
Others	-	-	-	-
CF from financing activities	(4,040)	(5,455)	(8,741)	(5,106)
Net Cash flow	5,069	1,291	1,232	5,957
Exchange difference	-	-	-	-
Opening Cash	729	1,317	1,694	2,926
Bank bal +unclaimed dvd.	(4,482)	-	-	-
Cash c/f to balance sheet	1,317	1,694	2,926	8,883

Source: Company, ICICI Direct Research

Key ratios				
	FY17	FY18	FY19E	FY20E
Per share data (₹)				
EPS	60.0	62.6	74.7	80.5
Cash EPS	65.9	73.0	90.8	98.2
BV	237.6	262.5	281.8	324.6
DPS	24.0	12.0	35.0	37.7
Cash Per Share	9.3	12.1	21.6	65.5
Operating Ratios (%)				
EBIT Margin	20.3	19.7	20.0	20.0
PBT Margin	21.9	20.9	21.1	21.2
PAT Margin	18.1	17.4	16.7	16.3
Debtor days	84	88	88	88
Creditor days	-	-	-	-
Return Ratios (%)				
RoE	25.3	23.8	26.5	24.8
RoCE	29.0	27.4	32.0	31.0
RoIC	28.9	29.0	35.0	38.8
Valuation Ratios (x)				
P/E	16.0	15.3	12.8	11.9
EV / EBITDA	13.0	11.5	9.1	7.9
EV / Net Sales	2.9	2.6	2.2	1.9
Market Cap / Sales	2.9	2.7	2.2	2.0
Price to Book Value	4.0	3.7	3.4	3.0
Solvency Ratios				
Debt/EBITDA	0.1	0.0	0.0	0.0
Debt / Equity	0.0	0.0	0.0	0.0
Current Ratio	1.2	1.5	1.5	1.5
Quick Ratio	1.2	1.5	1.5	1.5

Source: Company, ICICI Direct Research



#### RATING RATIONALE

ICICI Direct endeavours to provide objective opinions and recommendations. ICICI Direct assigns ratings to its stocks according to their notional target price vs. current market price and then categorises them as Strong Buy, Buy, Hold and Sell. The performance horizon is two years unless specified and the notional target price is defined as the analysts' valuation for a stock.

Strong Buy: >15%/20% for large caps/midcaps, respectively, with high conviction;

Buy: >10%/15% for large caps/midcaps, respectively;

Hold: Up to  $\pm$ -10%; Sell: -10% or more;



Pankaj Pandey

Head - Research

pankaj.pandey@icicisecurities.com

ICICI Direct Research Desk,
ICICI Securities Limited,
1st Floor, Akruti Trade Centre,
Road No 7, MIDC,
Andheri (East)
Mumbai – 400 093
research@icicidirect.com



#### ANALYST CERTIFICATION

We /l, Devang Bhatt, PGDBM, Deepti Tayal, MBA, Research Analysts, authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect our views about the subject issuer(s) or securities. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report.

#### Terms & conditions and other disclosures:

ICICI Securities Limited (ICICI Securities) is a full-service, integrated investment banking and is, inter alia, engaged in the business of stock brokering and distribution of financial products. ICICI Securities Limited is a Sebi registered Research Analyst with Sebi Registration Number – INH00000990. ICICI Securities Limited Sebi Registration is INZ000183631 for stock broker. ICICI Securities is a wholly-owned subsidiary of ICICI Bank which is India's largest private sector bank and has its various subsidiaries engaged in businesses of housing finance, asset management, life insurance, general insurance, venture capital fund management, etc. ("associates"), the details in respect of which are available on www.icicibank.com.

ICICI Securities is one of the leading merchant bankers/ underwriters of securities and participate in virtually all securities trading markets in India. We and our associates might have investment banking and other business relationship with a significant percentage of companies covered by our Investment Research Department. ICICI Securities generally prohibits its analysts, persons reporting to analysts and their relatives from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover.

The information and opinions in this report have been prepared by ICICI Securities and are subject to change without any notice. The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of ICICI Securities. While we would endeavour to update the information herein on a reasonable basis, ICICI Securities is under no obligation to update or keep the information current. Also, there may be regulatory, compliance or other reasons that may prevent ICICI Securities from doing so. Non-rated securities indicate that rating on a particular security has been suspended temporarily and such suspension is in compliance with applicable regulations and/or ICICI Securities policies, in circumstances where ICICI Securities might be acting in an advisory capacity to this company, or in certain other circumstances.

This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. ICICI Securities will not treat recipients as customers by virtue of their receiving this report. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. The recipient should independently evaluate the investment risks. The value and return on investment may vary because of changes in interest rates, foreign exchange rates or any other reason. ICICI Securities accepts no liabilities whatsoever for any loss or damage of any kind arising out of the use of this report. Past performance is not necessarily a guide to future performance. Investors are advised to see Risk Disclosure Document to understand the risks associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to

ICICI Securities or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months.

ICICI Securities or its associates might have received any compensation from the companies mentioned in the report during the period preceding twelve months from the date of this report for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory service in a merger or specific transaction.

ICICI Securities or its associates might have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the companies mentioned in the report in the past twelve months.

ICICI Securities encourages independence in research report preparation and strives to minimize conflict in preparation of research report. ICICI Securities or its associates or its analysts did not receive any compensation or other benefits from the companies mentioned in the report or third party in connection with preparation of the research report. Accordingly, neither ICICI Securities nor Research Analysts and their relatives have any material conflict of interest at the time of publication of this report.

It is confirmed that Devang Bhatt, PGDBM, Deepti Tayal, MBA, Research Analysts of this report have not received any compensation from the companies mentioned in the report in the preceding twelve months.

Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions.

ICICI Securities or its subsidiaries collectively or Research Analysts or their relatives do not own 1% or more of the equity securities of the Company mentioned in the report as of the last day of the month preceding the publication of the research report.

Since associates of ICICI Securities are engaged in various financial service businesses, they might have financial interests or beneficial ownership in various companies including the subject company/companies mentioned in this report.

It is confirmed that Devang Bhatt, PGDBM, Deepti Tayal, MBA, Research Analysts do not serve as an officer, director or employee of the companies mentioned in the report.

ICICI Securities may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report.

Neither the Research Analysts nor ICICI Securities have been engaged in market making activity for the companies mentioned in the report

We submit that no material disciplinary action has been taken on ICICI Securities by any Regulatory Authority impacting Equity Research Analysis activities.

This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject ICICI Securities and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction.